TROG Cancer Research
Members Login   CQMS Login

TROG 11.03 (P_LUNG GP)

Overview

Title: A Randomised Phase III Trial of High Dose Palliative Radiotherapy (HDPRT) Versus Concurrent Chemotherapy + HDPRT (C-HDPRT) in Patients with Good Performance Status, Locally Advanced/Small Volume Metastatic Non Small Cell Lung Cancer (NSCLC) Not Suitable for Radical Chemo-Radiotherapy

Final accrual:  76

Closed to follow-up date: 31 July 2018

Trial chair: Associate Professor Margot Lehman, Princess Alexandra Hospital, QLD 

Trial contact:
Adrienne See
Clinical Trial Coordinator
Princess Alexandra Hospital, QLD
Phone: +61 7 3176 9116
Email: Adrienne.See@health.qld.gov.au

Primary sponsor: Trans Tasman Radiation Oncology Group (TROG)

Clinical trial registration:
Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12612001211853


Trial documentation

Protocol
Case Report Forms
Certificate of Currency


Quality Assurance

Radiation Therapy Quality Assurance Guidelines
RTQA Guidelines

QA Checklist - Post RT
QA Checklist - Chemotherapy

 

TROG explores advances in radiotherapy that influence clinical practice worldwide.


Latest News

  • 15 May 2020

    The diagnosis of ductal carcinoma in situ (DCIS) of the breast has increased substantially due to mammographic screening, and now accounts for 25 per cent of screen-detected breast cancer. Over 1,600 women are diagnosed with DCIS in Australia every year. However, unlike invasive breast cancer, there are limited knowledge and experience for patients and clinicians to draw on when this now common diagnosis of DCIS is made.

  • 15 Apr 2020

    Prostate cancer is one of the most common cancers amongst men, with one in six men diagnosed before their 85th birthday (Cancer Australia). In fact, in 2019 alone over 19,000 men in Australia were diagnosed with prostate cancer.

  • 06 Apr 2020

    p style="text-align: center;">_ src="/sitefiles/trogcomau/trog_team_2020.jpg" style="height: 333px; width: 500px;" />   covid-19 and the regulations around social distancing has affected an increasing number of events across australia, including the yearly gathering of radiation...

  • 01 Apr 2020

    The coronavirus health pandemic is a challenging time for us all – personally and professionally. We know that the changes and safety precautions required as a result of the pandemic have had significant impacts on the way we operate clinical trials – those that are underway, set t...

  • 15 Jan 2020

    _ src="/sitefiles/trogcomau/fbp_0378_large.jpg" /> new research by the university of new south wales (unsw), presented at the clinical oncology society of australia’s (cosa) annual scientific meeting (asm) found that increased use of radiation therapy for prostate cancer patients c...

  • 13 Sep 2019

    trog cancer research will work with clinicians at townsville hospital, as well as other national experts, to implement a research program aimed at understanding how to best use new mri linac technology to benefit cancer patients. img src="/sitefiles/trogcomau/tro_trog_cancer_resear...

  • 09 Sep 2019

    TROG Cancer Research is currently in the final year of their 2017-2019 strategic plan. On Friday 2 August 2019, we held a strategic planning meeting with key stakeholders to discuss the direction and focus for the upcoming three years.  The workshop facilitated by Ms Alison Evans, Hea...

  • 03 Sep 2019

    trog cancer research are proud to announce that we have two new additions to the trog cancer research board of directors. joining our team is professor annette haworth and denis byron. appointed as a non-radiation oncology director, annette is an accredited medical physicist wh...